Zevra Therapeutics, Inc. (ZVRA)
| Market Cap | 540.30M +2.1% |
| Revenue (ttm) | 147.76M +75.1% |
| Net Income | 74.97M +120.8% |
| EPS | 1.23 +128.3% |
| Shares Out | 59.50M |
| PE Ratio | 7.39 |
| Forward PE | 9.54 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,941,991 |
| Open | 10.64 |
| Previous Close | 11.16 |
| Day's Range | 9.01 - 10.65 |
| 52-Week Range | 8.01 - 15.04 |
| Beta | 0.99 |
| Analysts | Strong Buy |
| Price Target | 23.75 (+161.56%) |
| Earnings Date | Nov 3, 2026 |
About ZVRA
Zevra Therapeutics, Inc., a commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States. The company develops its products through Ligand Activated Technology platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 3 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase 3 clinical trial to treat narcolepsy. The company is developing Celiprolol, an investigational product candidate that is under Phase 3 clinical tr... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 9 analysts, the average rating for ZVRA stock is "Strong Buy." The 12-month stock price target is $23.75, which is an increase of 161.56% from the latest price.
News
Zevra reports European negative opinion on MAA for arimoclomol
Zevra Therapeutics (ZVRA) announced that the Committee for Medicinal Products for Human Use, or CHMP, of the European Medicines Agency, or EMA, has adopted a negative opinion on the Marketing…
Zevra Therapeutics Announces Final CHMP Opinion on Arimoclomol for the Treatment of Niemann-Pick Disease Type C (NPC) in the European Union
European Commission to make final decision on arimoclomol MAA following negative CHMP opinion European Commission to make final decision on arimoclomol MAA following negative CHMP opinion
Zevra Therapeutics reports Q3 EPS 26c, consensus 18c
Reports Q3 revenue $37.76M, consensus $37.41M. “In the third quarter, we made continued progress across our business, building on MIPLYFFA’s commercial performance in the U.S. and advancing our pipeli...
Zevra Therapeutics Earnings Call Transcript: Q3 2026
Q3 revenue rose 45% YoY to $37.8 million, with MIPLYFFA U.S. sales of $34 million and net income of $19.2 million, including a $5.5 million non-cash warrant valuation credit. Cash and investments were $270.9 million; an infant-label sNDA is planned for Q1 2027.
Zevra Therapeutics Earnings release: Q3 2026
Zevra Therapeutics released its Q3 2026 earnings on November 3, 2026, summarizing the period's financial results.
Zevra Therapeutics Quarterly report: Q3 2026
Zevra Therapeutics has published its Q3 2026 quarterly earnings report on November 3, 2026.
Zevra Reports Third Quarter 2026 Financial Results and Corporate Update
$37.8 million net revenue for Q3 2026 , driven by $34.0 million in revenue from MIPLYFFA
Zevra Therapeutics Announces Details for Q3 2026 Financial Results Call
BOSTON, Oct. 20, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on bringing life-changing therapeutics to people living ...
Zevra Therapeutics Slides: Corporate presentation
Zevra Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on October 1, 2026.
Zevra Therapeutics Transcript: H.C. Wainwright 28th Annual Global Investment Conference
Significant progress includes expanding the diagnosed population for MIPLYFFA, leveraging updated clinical guidelines, and investing in data-driven patient identification. Global expansion and a strong balance sheet support ongoing pipeline development and strategic flexibility.
Zevra Therapeutics Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
Focused on redefining rare disease care, the company has rapidly grown its U.S. market for Niemann-Pick type C, expanded globally, and advanced a promising pipeline. Strong financials and robust patient support underpin its strategy, with key regulatory and clinical milestones ahead.
Zevra Therapeutics Slides: Corporate presentation
Zevra Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on September 14, 2026.
Zevra Therapeutics Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
The conference highlighted robust commercial progress in rare diseases, with strong U.S. and global expansion for NPC, a growing adult patient base, and a well-capitalized position. Ongoing regulatory efforts and a solid pipeline, including VEDS, support long-term growth.
Zevra Therapeutics to Present at Upcoming Investor Conferences
BOSTON, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on bringing life-changing therapeutics to people living...
Zevra Therapeutics to Present New Long-Term Real-World Data on MIPLYFFA® in Niemann-Pick Disease Type C (NPC) at the 2026 SSIEM Annual Symposium
BOSTON, Aug. 25, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on bringing life-changing therapeutics to people living ...
Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BOSTON, Mass., Aug. 21, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on bringing life-changing therapeutics to people ...
Zevra Therapeutics Transcript: Canaccord Genuity's 46th Annual Growth Conference
MIPLYFFA's U.S. launch is driving growth in both adult and pediatric Niemann-Pick type C patients, with integrated strategies expanding the addressable market. European expansion is ongoing, and the pipeline includes a late-stage program for Vascular Ehlers-Danlos Syndrome. Strong financials support disciplined investment and targeted business development.
Zevra Therapeutics price target lowered to $23 from $24 at Guggenheim
Guggenheim analyst Eddie Hickman lowered the firm’s price target on Zevra Therapeutics (ZVRA) to $23 from $24 and keeps a Buy rating on the shares.
Zevra Therapeutics price target raised to $28 from $25 at Citizens
Citizens raised the firm’s price target on Zevra Therapeutics (ZVRA) to $28 from $25 and keeps an Outperform rating on the shares. Zevra reported strong Q2 results driven by MIPLYFFA…
Zevra Therapeutics Earnings Call Transcript: Q2 2026
Q2 2026 net revenue rose 53% year-over-year to $39.7 million, led by strong MIPLYFFA sales and expanding adoption in both pediatric and adult NPC patients. Cash reserves reached $260.2 million, supporting ongoing pipeline and global expansion, while regulatory re-examination for arimoclomol in Europe continues.
Zevra Therapeutics Earnings release: Q2 2026
Zevra Therapeutics released its Q2 2026 earnings on August 5, 2026, summarizing the period's financial results.
Zevra Therapeutics Quarterly report: Q2 2026
Zevra Therapeutics has published its Q2 2026 quarterly earnings report on August 5, 2026.
Zevra Reports Second Quarter 2026 Financial Results and Corporate Update
$39.7 million net revenue for Q2 2026, driven by $30.2 million in revenue from MIPLYFFA 53% increase in total net revenue over Q2 2025 Operational execution fueled strong cash position of $260.2 milli...
Zevra Therapeutics Slides: Corporate presentation
Zevra Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on August 5, 2026.
Zevra Therapeutics to Present at the Canaccord Genuity Annual Growth Conference
BOSTON, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on bringing life-changing therapeutics to people living ...